OncoSil Medical Limited (OSL.AX)
AUD 0.0
(0.0%)
AUD 0.0
(0.0%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 | -11.98 Million AUD | 4.54% |
| 2023 | -12.55 Million AUD | -10.03% |
| 2022 | -11.4 Million AUD | 1.87% |
| 2021 | -11.62 Million AUD | -61.27% |
| 2020 | -7.2 Million AUD | 41.91% |
| 2019 | -12.41 Million AUD | 5.17% |
| 2018 | -13.08 Million AUD | -21.09% |
| 2017 | -10.8 Million AUD | -21.83% |
| 2016 | -8.87 Million AUD | -205.83% |
| 2015 | -2.9 Million AUD | 30.32% |
| 2014 | -4.16 Million AUD | -321.38% |
| 2013 | -988.03 Thousand AUD | -138.22% |
| 2012 | -414.74 Thousand AUD | 17.73% |
| 2011 | -504.11 Thousand AUD | -23836.89% |
| 2010 | -2106.00 AUD | 99.77% |
| 2009 | -915.08 Thousand AUD | 72.91% |
| 2008 | -3.37 Million AUD | -60.8% |
| 2007 | -2.1 Million AUD | -583.77% |
| 2006 | -307.27 Thousand AUD | -1118.73% |
| 2005 | -25.21 Thousand AUD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 FY | -13.26 Million AUD | -5.68% |
| 2024 Q2 | -6.61 Million AUD | 0.0% |
| 2024 Q4 | -6.64 Million AUD | 0.0% |
| 2023 FY | -12.55 Million AUD | -10.03% |
| 2023 Q4 | -6.21 Million AUD | 0.0% |
| 2023 Q2 | -6.33 Million AUD | 0.0% |
| 2022 FY | -11.4 Million AUD | 1.87% |
| 2022 Q2 | -6.16 Million AUD | 0.0% |
| 2022 Q4 | -5.24 Million AUD | 0.0% |
| 2021 Q4 | -6.13 Million AUD | 0.0% |
| 2021 Q2 | -5.49 Million AUD | 0.0% |
| 2021 FY | -11.62 Million AUD | -61.27% |
| 2020 Q4 | -2.57 Million AUD | 0.0% |
| 2020 FY | -7.2 Million AUD | 41.91% |
| 2020 Q2 | -4.63 Million AUD | 0.0% |
| 2019 FY | -12.41 Million AUD | 5.17% |
| 2019 Q4 | -5.32 Million AUD | 0.0% |
| 2019 Q2 | -5.27 Million AUD | 0.0% |
| 2018 Q4 | -4.08 Million AUD | 0.0% |
| 2018 FY | -13.08 Million AUD | -21.09% |
| 2018 Q2 | -4.55 Million AUD | 0.0% |
| 2017 Q2 | -3.32 Million AUD | 0.0% |
| 2017 FY | -10.8 Million AUD | -21.83% |
| 2017 Q4 | -3.97 Million AUD | 0.0% |
| 2016 FY | -8.87 Million AUD | -205.83% |
| 2016 Q2 | -1.86 Million AUD | 0.0% |
| 2016 Q4 | -3.16 Million AUD | 0.0% |
| 2015 FY | -2.9 Million AUD | 30.32% |
| 2015 Q4 | -603.42 Thousand AUD | 0.0% |
| 2015 Q2 | -2.29 Million AUD | 0.0% |
| 2014 Q4 | -2.28 Million AUD | 0.0% |
| 2014 FY | -4.16 Million AUD | -321.38% |
| 2014 Q2 | -1.87 Million AUD | 0.0% |
| 2013 Q4 | -674.81 Thousand AUD | -173.8% |
| 2013 Q1 | -103.64 Thousand AUD | 0.0% |
| 2013 Q2 | -207.27 Thousand AUD | -99.98% |
| 2013 Q3 | -246.45 Thousand AUD | -18.91% |
| 2013 FY | -988.03 Thousand AUD | -138.22% |
| 2012 Q2 | -103.64 Thousand AUD | 17.76% |
| 2012 FY | -414.74 Thousand AUD | 17.73% |
| 2012 Q3 | -103.64 Thousand AUD | 0.0% |
| 2012 Q1 | -126.02 Thousand AUD | 0.0% |
| 2012 Q4 | -103.64 Thousand AUD | 0.0% |
| 2011 Q1 | -526.50 AUD | 0.0% |
| 2011 Q3 | -126.02 Thousand AUD | 0.0% |
| 2011 FY | -504.11 Thousand AUD | -23836.89% |
| 2011 Q4 | -126.02 Thousand AUD | 0.0% |
| 2011 Q2 | -126.02 Thousand AUD | -23836.89% |
| 2010 Q3 | -526.50 AUD | 0.0% |
| 2010 Q2 | -526.50 AUD | 99.64% |
| 2010 FY | -2106.00 AUD | 99.77% |
| 2010 Q4 | -526.50 AUD | 0.0% |
| 2010 Q1 | -145.57 Thousand AUD | 0.0% |
| 2009 FY | -915.08 Thousand AUD | 72.91% |
| 2009 Q4 | -145.57 Thousand AUD | 0.0% |
| 2009 Q1 | -844.62 Thousand AUD | 0.0% |
| 2009 Q2 | -145.57 Thousand AUD | 82.76% |
| 2009 Q3 | -145.57 Thousand AUD | 0.0% |
| 2008 Q2 | -844.62 Thousand AUD | -60.8% |
| 2008 Q1 | -525.27 Thousand AUD | 0.0% |
| 2008 FY | -3.37 Million AUD | -60.8% |
| 2008 Q4 | -844.62 Thousand AUD | 0.0% |
| 2008 Q3 | -844.62 Thousand AUD | 0.0% |
| 2007 Q4 | -525.27 Thousand AUD | 0.0% |
| 2007 Q2 | -525.27 Thousand AUD | -583.77% |
| 2007 Q1 | -76.81 Thousand AUD | 0.0% |
| 2007 FY | -2.1 Million AUD | -583.77% |
| 2007 Q3 | -525.27 Thousand AUD | 0.0% |
| 2006 FY | -307.27 Thousand AUD | -1118.73% |
| 2006 Q4 | -76.81 Thousand AUD | 0.0% |
| 2006 Q2 | -76.81 Thousand AUD | -1122.41% |
| 2006 Q1 | -6284.25 AUD | 0.0% |
| 2006 Q3 | -76.81 Thousand AUD | 0.0% |
| 2005 FY | -25.21 Thousand AUD | 0.0% |
| 2005 Q3 | -6284.25 AUD | 0.0% |
| 2005 Q2 | -6284.25 AUD | 0.0% |
| 2005 Q4 | -6284.25 AUD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| 4DMedical Limited | -27.96 Million AUD | 57.148% |
| Adherium Limited | -11.98 Million AUD | 0.009% |
| Aroa Biosurgery Limited | -9.78 Million AUD | -22.441% |
| Atomo Diagnostics Limited | -4.36 Million AUD | -174.774% |
| Anteris Technologies Ltd | -66.63 Million AUD | 82.015% |
| Control Bionics Limited | -5.92 Million AUD | -102.12% |
| CardieX Limited | -4.63 Million AUD | -158.631% |
| Compumedics Limited | -269 Thousand AUD | -4355.096% |
| Cochlear Limited | 521.5 Million AUD | 102.298% |
| CleanSpace Holdings Limited | -4.81 Million AUD | -148.947% |
| Cyclopharm Limited | -9.22 Million AUD | -29.915% |
| EMVision Medical Devices Ltd | -1.61 Million AUD | -642.328% |
| Nova Eye Medical Limited | -3.79 Million AUD | -215.623% |
| HeraMED Limited | -6.42 Million AUD | -86.438% |
| Imricor Medical Systems, Inc. | -17.57 Million AUD | 31.812% |
| ImpediMed Limited | -19.03 Million AUD | 37.044% |
| InhaleRx Limited | -1.38 Million AUD | -764.358% |
| LBT Innovations Limited | -4.74 Million AUD | -152.831% |
| Micro-X Limited | -13.02 Million AUD | 8.005% |
| Neurotech International Limited | -5.58 Million AUD | -114.586% |
| PolyNovo Limited | 1.16 Million AUD | 1130.456% |
| Respiri Limited | -7 Million AUD | -71.198% |
| SomnoMed Limited | -3.84 Million AUD | -211.984% |
| Universal Biosensors, Inc. | -16.68 Million AUD | 28.154% |
| Uscom Limited | -2.4 Million AUD | -398.439% |
| Visioneering Technologies, Inc. | -5.85 Million AUD | -104.714% |